Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

BioProcess International reviews key biotech trends from the first half of 2026, including US onshoring, China's biologics ...

The company recently wowed investors with clinical trial results.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so ...

The GLP-1 trade has matured from a single-stock story into a tiered opportunity set as demand for obesity therapeutics keeps ...

PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at ...

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.

Another wave of layoffs has hit one of the Bay Area's biggest biotech companies—and the latest cuts push a troubling trend ...

Michael Yee, UBS biotech analyst, joins 'The Exchange' to discuss Yee's thoughts on biotech stocks, what's driving the ...

Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or 'Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter ...

They have at least one thing in common: An exciting pipeline.